Analyzing Alumis (ALMS) & Its Peers

Alumis (NASDAQ:ALMS) is one of 846 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Alumis to similar companies based on the strength of its institutional ownership, dividends, analyst recommendations, earnings, valuation, profitability and risk.

Analyst Ratings

This is a summary of current ratings and target prices for Alumis and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1	1	11	1	2.86
Alumis Competitors	9904	15278	45630	1595	2.54

Alumis presently has a consensus target price of $33.27, indicating a potential upside of 402.61%. As a group, “Biotechnology” companies have a potential upside of 120.26%. Given Alumis’ stronger consensus rating and higher possible upside, research analysts plainly believe Alumis is more favorable than its rivals.

Valuation and Earnings

This table compares Alumis and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alumis	$24.05 million	-$243.32 million	-1.72
Alumis Competitors	$704.22 million	$10.96 million	-15.00

Alumis’ rivals have higher revenue and earnings than Alumis. Alumis is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Alumis and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alumis	-5,933.46%	-93.15%	-74.50%
Alumis Competitors	-12,283.59%	-195.39%	-30.85%

Institutional & Insider Ownership

47.7% of shares of all “Biotechnology” companies are held by institutional investors. 33.7% of Alumis shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Alumis has a beta of -0.28, meaning that its stock price is 128% less volatile than the S&P 500. Comparatively, Alumis’ rivals have a beta of 1.15, meaning that their average stock price is 15% more volatile than the S&P 500.

Summary

Alumis beats its rivals on 7 of the 12 factors compared.

About Alumis

Alumis is a clinical-stage biopharmaceutical company developing medicines for autoimmune and inflammatory diseases. The company uses data and computational tools to support the discovery and development of targeted treatments. Its lead investigational program, ESK-001, is an oral, selective TYK2 inhibitor being studied for conditions including plaque psoriasis and systemic lupus erythematosus. Alumis is also advancing other drug candidates for immune-mediated diseases. These medicines remain in clinical development and are not approved for commercial use.